UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 311, 2025

KESTRA MEDICAL TECHNOLOGIES, LTD.

(Exact name of Registrant as Specified in Its Charter)


Bermuda	001-42549	Not Applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3933 Lake Washington Blvd NE Suite 200
Kirkland, Washington		98033
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: (425) 279-8002

    

     Not applicable

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, par value $1.00 per share	KMTS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.07.02 SubmissionResults of MattersOperations toand aFinancial Vote of Security HoldersCondition.

~~The~~On September 11, 2025, Kestra Medical Technologies, Ltd. (the “Company”) ~~2025~~issued ~~annual~~a ~~general~~press ~~meeting~~release ofannouncing ~~shareholders~~its ~~(the~~financial ~~“2025~~results ~~Annual~~for ~~Meeting”)~~the ~~was~~fiscal ~~held~~quarter onended ~~September~~July 331, 2025. ~~The~~A ~~total~~copy ~~number~~ of the ~~Company’s~~press ~~common shares voted in person or by proxy at the 2025 Annual Meeting was 48~~release,~~835,102,~~ ~~representing~~dated ~~approximately~~September ~~95% of the 51~~11,~~348,656~~ ~~shares that were outstanding and entitled to vote as of July 7,~~ 2025, ~~the~~is ~~record~~furnished ~~date~~hereto ofas ~~the~~Exhibit ~~2025 Annual Meeting~~99.1 ~~Voting~~and ~~results~~is ~~for~~incorporated ~~each~~herein ~~matter~~by ~~submitted to a vote at the 2025 Annual Meeting are provided below~~reference.

~~Proposal~~The foregoing information in this Item 2.02 (including Exhibit 99.1 –attached ~~Election~~hereto) shall not be deemed “filed” for purposes of ~~Directors~~Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any registration statement or any other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

TheItem shareholders9.01 electedFinancial eachStatements of the two persons named below to serve as Class I directors until the Company’s 2028 annual meeting of shareholders and until their successors are duly elected and qualified, with the vote totals as set forth in the table below:Exhibits.

Nominee	For	Against	Abstain
ExhibitNumber		Description
Conor Hanley	43,121,331	3,640,519	14,870
99.1		Press Release of Kestra Medical Technologies, Ltd., dated September 11, 2025
Elizabeth Kwo	43,118,417	3,643,439	14,864
104		Cover Page Interactive Data File, formatted in Inline XBRL.

~~Proposal 2 – Ratification of Independent Registered Public Accounting Firm~~ SIGNATURES

~~The~~Pursuant ~~shareholders~~to ~~ratified~~ the ~~appointment~~requirements of ~~PricewaterhouseCoopers as~~ the ~~Company's~~Securities ~~independent~~Exchange ~~registered~~Act ~~public~~of ~~accounting~~1934, ~~firm for~~ the ~~fiscal~~registrant ~~year~~has ~~ending~~duly ~~April~~caused ~~30,~~this ~~2026,~~report ~~with~~to ~~the~~be ~~vote~~signed ~~totals~~on ~~set~~its ~~forth~~behalf inby the ~~table~~undersigned ~~below:~~hereunto duly authorized.

For	Against	Abstain
		Kestra Medical Technologies, Ltd.
48,814,793	5,444	14,865
Date: September 11, 2025		By:	/s/ Brian Webster
		Name:	Brian Webster
		Title:	President and Chief Executive Officer

Proposal 3 – Approval of 2025 Employee Stock Purchase Plan

The shareholders approved the Kestra Medical Technologies, Ltd. 2025 Employee Stock Purchase Plan, with the vote totals set forth in the table below:

For	Against	Abstain
45,801,106	975,504	110

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Kestra Medical Technologies, Ltd.
Date: September 4, 2025	By:	/s/ Brian Webster
	Name:	Brian Webster
	Title:	President and Chief Executive Officer

Filing Compare · KESTRA MEDICAL TECHNOLOGIES, LTD.